ESR1 and breast carcinoma: Tamoxifen, a selective ER modulator, is the most commonly used neoadjuvant and adjuvant endocrine therapy in treatment of patients with ER-α+ breast cancer [4], tamoxifen targets the proliferation-stimulating effects of ERs in breast cancer [5].